U. Deligezer Et Al. , "Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.," Clinica chimica acta; international journal of clinical chemistry , vol.411, pp.1452-6, 2010
Deligezer, U. Et Al. 2010. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.. Clinica chimica acta; international journal of clinical chemistry , vol.411 , 1452-6.
Deligezer, U., Yaman, F., Darendeliler, E., Dizdar, Y., Holdenrieder, S., Kovancilar, M., ... Dalay, N.(2010). Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.. Clinica chimica acta; international journal of clinical chemistry , vol.411, 1452-6.
Deligezer, U Et Al. "Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.," Clinica chimica acta; international journal of clinical chemistry , vol.411, 1452-6, 2010
Deligezer, U Et Al. "Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.." Clinica chimica acta; international journal of clinical chemistry , vol.411, pp.1452-6, 2010
Deligezer, U. Et Al. (2010) . "Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.." Clinica chimica acta; international journal of clinical chemistry , vol.411, pp.1452-6.
@article{article, author={U Deligezer Et Al. }, title={Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.}, journal={Clinica chimica acta; international journal of clinical chemistry}, year=2010, pages={1452-6} }